Dr Agarwal’s merger gets NCLT nod: key dates 2026

What the NCLT order changes

Dr. Agarwal's Health Care Limited has disclosed that the National Company Law Tribunal (NCLT), Chennai Bench, has sanctioned its scheme of amalgamation involving Dr. Agarwal's Eye Hospital Limited. The order was pronounced in a hearing held on September 30, 2026, and later uploaded to the NCLT website on October 5, 2026. The company said it is awaiting the certified copy of the order. It also stated that the certified copy will be made available on the company website once received.

The scheme provides for Dr. Agarwal's Eye Hospital Limited to merge with and into Dr. Agarwal's Health Care Limited. The filing places the scheme under Sections 230 to 232 of the Companies Act, 2013. While the tribunal sanction is a major procedural milestone, the company has also highlighted that the operative date still depends on completion of specified conditions in the scheme.

Which entities are merging and under what law

The transaction structure described is an amalgamation where Dr. Agarwal's Eye Hospital Limited acts as the transferor company and Dr. Agarwal's Health Care Limited is the transferee company. The legal framework cited is Sections 230 to 232 of the Companies Act, 2013, which governs compromises, arrangements, and mergers.

The disclosures consistently refer to this as a scheme-driven process, which typically involves regulatory review, stakeholder meetings, and tribunal sanction. In this case, the company’s updates show the process moved through each step, including stock exchange observations, tribunal directions to hold meetings, stakeholder voting, and finally the NCLT sanction.

Appointed date versus operative date: the key distinction

The company has stated that the scheme shall be effective from the “Appointed Date,” defined as the opening of business on April 1, 2026. This date matters because it anchors when the amalgamation is treated as effective for the purposes specified in the scheme.

Separately, the “operative date” is defined as the first day of the calendar month immediately following completion of all conditionalities mentioned in Clause 24 of the scheme. This means the scheme’s practical implementation timeline is tied to the fulfilment of those conditions, and not solely to the tribunal’s sanction date.

A five-month gap and the retroactive accounting effect

The gap between the appointed date (April 1, 2026) and the sanction date (September 30, 2026) indicates a retroactive accounting effect for over five months, as described in the provided context. Based on that context, financial statements for the period between April and September 2026 will likely require restatement or consolidation adjustments to reflect the combined entity’s performance from the start of the fiscal year.

This is a common feature of schemes that use an appointed date aligned to the beginning of a financial year. For investors tracking quarterly performance and year-to-date numbers, the key point is that the appointed date sets an accounting reference point, while the operative date depends on the scheme’s completion mechanics.

How the merger process unfolded: hearings, meetings, and approvals

Before the sanction, the company had indicated that the NCLT Chennai Bench would hear its amalgamation petition on August 19, 2026. Stakeholders wishing to support or oppose the scheme were required to submit their notice of intention to the petitioner’s advocate two days before the hearing.

The stakeholder voting process took place earlier. Dr. Agarwal’s Health Care Limited secured shareholder approval for the amalgamation on July 2, 2026, with 99.95% of votes in favour, subject to NCLT sanction. The shareholder meeting was convened by the NCLT and held at The Music Academy in Chennai.

On the creditor side, the company disclosed approvals across categories. Unsecured creditors approved the scheme on July 2, 2026, with 100% approval and 11,10,20,428 votes cast in favour. The secured creditors also approved the scheme at a meeting held on July 2, 2026, in Chennai, as mandated by the NCLT.

Earlier regulatory steps: BSE observations and SEBI conditions

The filings also refer to a key earlier milestone at the stock exchange level. Dr. Agarwal's Eye Hospital Limited secured BSE approval for the amalgamation scheme with “no adverse observations” dated February 17, 2026. The approval was accompanied by 17 specific SEBI compliance conditions and required submission to the NCLT within six months.

In parallel, the NCLT had earlier approved the convening of meetings for shareholders and creditors. That tribunal order was pronounced on May 5, 2026, and uploaded on May 11, 2026. The same direction led to the July 2, 2026 meetings to consider and approve the proposed scheme.

Business context: scale of operations and reported revenue

The company has been described as India’s largest eye care services chain, providing consultations, surgeries, and specialised treatments for ocular health. In the context provided, the consolidation is presented as a step to streamline the group’s operations.

The group’s footprint was stated as 258 centers. The same context also reported trailing twelve-month (TTM) revenue of Rs 2,080 crore. These details frame why a group simplification exercise like this can be material for disclosures and reporting, particularly when the appointed date aligns with the start of the fiscal year.

Key dates and facts at a glance

Market impact: what investors should track from here

The tribunal sanction reduces a key execution uncertainty, but the company’s disclosures make it clear that completion is still linked to meeting the conditions specified in Clause 24 of the scheme. As a result, the operative date remains dependent on those conditionalities being completed.

From a reporting perspective, the appointed date of April 1, 2026, coupled with a later sanction date, creates a period where the combined entity’s results may need to be reflected for the interim months in the financial year, consistent with the retroactive effect highlighted in the context. Investors generally watch for subsequent corporate filings that clarify when conditions are completed, when the operative date is triggered, and how the company presents the financial impact.

Why this amalgamation matters

This amalgamation is positioned as a consolidation of group entities into the listed company structure, based on the scheme description. The approvals already recorded across shareholders, secured creditors, and unsecured creditors show strong stakeholder support in the process as reported. The legal pathway under Sections 230 to 232, along with the NCLT’s directed meetings and final sanction, reflects a structured and court-supervised mechanism.

The sequence of dates also matters for comparability of results across periods. With the appointed date set at the start of the fiscal year, the accounting and presentation choices around consolidation for April to September 2026 become a practical point of attention for readers tracking performance.

What happens next

Dr. Agarwal’s Health Care Limited has said it is awaiting the certified copy of the NCLT order and will place it on its website upon receipt. The scheme’s operative date, as described, will occur after completion of the Clause 24 conditionalities and will fall on the first day of the next calendar month.

Investors will likely look for the next set of corporate disclosures that confirm receipt of the certified order copy, completion of scheme conditions, and the final operative date that triggers implementation steps.